EUCTR2015-001593-18-AT进行中（未招募）1 期
A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans - [11C]erlotinib
Medizinische Universiät Wien0 个研究点目标入组 87 人开始时间: 2015年4月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Non-smokers
- •Age: >18 and < 55 years old
- •No disease interfering with the study objectives (at investigators´ discretion)
- •Normotensive after 5 min rest
- •Normofrequent after 5 min rest
- •No contraindication for MRI
- •No known hypersensitivity to any of the components of the administered substances and diagnostics
- •Volunteers must sign the informed consent prior to inclusion in the study
- •Inclusion criteria for patients of group 5 only:
- •oAbility to comprehend the full nature and purpose of the study, including possible risks and side effects
- •oPatients with an intrahepatic shunt undergoing measurement of portosystemic pressure gradient to assess shunt function for clinical routine purposes (one previous measurement is required)
- •oModerate nicotine consumption is allowed for this group
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 82
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Abnormalities found in blood and urine laboratory tests as part of the pretreatment screening or in any of the laboratory tests performed that the investigator considers clinically relevant
- •Presence of any ECG abnormalities, which the investigator considers clinically relevant
- •Abnormalities in the medical history (e.g. history of or current ethanol abuse, allergies, co-morbidities, anticoagulation with Marcoumar®) that might influence the outcome of the study or might result in inacceptable risks for the subject according to investigators judgment.
- •History of drug and alcohol abuse
- •Contraindication to arterial cannulation (e.g. intake of anticoagulants of any kind)
- •Blood donation within 1 month before the start of the study
- •Participation in a clinical study with radioactive substances if exposure exceeds the maximum foreseen radiation of the current guidelines
- •Intake of any medication during two weeks before the start of the study, which the investigator considers may affect the validity of the study, due to interference with CYP3A4, ABCB1 or ABCG2 (ABCB1 inducers such as St. John’s wort, docetaxel, etoposide, vincristine, cyclosporine, tacrolimus, macrolides, lovastatin, digoxin, digitoxin, carvedilol, rifampicin or inhibitors such as esomprazol, omeprazole, pantoprazole, lansoprazole, atorvastatin, itraconazol) or may cause potential harm to the subject (drug-drug interaction between tariquidar and loperamide or quinidine)
- •Subjects with Galactose-Intolerance, Lactase-Deficiency or Glucose-Galactose –Malabsorption (erlotinib tablets contain lactose)
- •For female subjects in child-bearing age: Pregnancy or breastfeeding
- •Exclusion criteria for patients of group 5 only:
- •oA medical condition or drug treatment interfering with the study objectives (at investigators´ discretion)
- •oAbsolute contraindication for PET/MRI investigation
- •oPatients with history of alcohol abuse who are currently abstinent
- •oPresence of any ECG or other abnormalities, which the investigator considers clinically relevant
- •oParticipation in a clinical study with radioactive substances if exposure exceeds the maximum foreseen radiation of the current guidelines
研究者
相似试验
尚未招募
不适用
Study on the effectiveness of tranexamic acid(drug) in reducing blood loss during hip surgeriesCTRI/2022/03/041001Vinayaka missions kirupananda variyar medical college and hospital
尚未招募
4 期
Warfarin pharmacogeneticsPACTR202103893112947Ilhaam Fredericks60
已完成
不适用
A prospective, randomized controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with interstitial lung diseaseinterstitial lung disease (ILD)JPRN-UMIN000004041agasaki University Hospital40
尚未招募
不适用
Study of transdermal drug patches used for acute pain in major public hospitalCTRI/2023/02/050112Seth GSMC and KEM Hospital
尚未招募
不适用
Effect of a Nutritional Supplement drink on the glycemic response among type 2 diabetes patientsCTRI/2015/04/005693Abbott Nutrition International India Abbott Healthcare Private Limited120